L-Ofloxacin
Antibiotic Resistant Infection
Jessa HospitalSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Antibiotic Resistant Infection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inulin Columbia University | Phase 2 | B |
POLY(ACETYL, ARGINYL)GLUCOSAMINE (25000-50000 MW) Synspira, Inc. | Phase 1 | CC |
Same molecule, other indications
L-Ofloxacin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →